Related Experiment Video

Updated: Aug 14, 2026

Direct Tracheal Instillation of Solutes into Mouse Lung
04:50

Direct Tracheal Instillation of Solutes into Mouse Lung

Published on: August 30, 2010

[Theophylline toxicity in infants]

M J López García1, M García Ballester, A Escribano Montaner

  • 1Servicio de Pediatría, Hospital Clínico Universitario de Valencia.

Anales Espanoles De Pediatria
|March 1, 1990
PubMed

Insights

Theophylline intoxication in infants is a significant risk, occurring in 9.5% of cases. Infants under 3 months are most vulnerable, highlighting the need for careful serum concentration monitoring.

Area of Science:

  • Pediatric Pharmacology
  • Neonatal Toxicology
  • Clinical Therapeutics

Context:

  • Theophylline is a bronchodilator used in infants.
  • Assessing risks and clinical features of theophylline intoxication is crucial for patient safety.
  • A 4-year comparative study was conducted to evaluate these factors.

Purpose:

  • To identify risk factors for theophylline intoxication in infants.
  • To describe the clinical manifestations of theophylline toxicity in this age group.
  • To provide evidence-based recommendations for theophylline use in neonates.

Summary:

  • The study found a 9.5% incidence of theophylline intoxication in infants.
  • Infants aged 3 months or younger showed a higher tendency towards intoxication.
  • Clinical manifestations included tachycardia, irritability, seizures, and severe metabolic disturbances, with no clear correlation between serum levels and severity.

Impact:

  • Theophylline should be used cautiously in infants, especially those under 3 months.
  • Close monitoring of serum theophylline concentrations is essential to prevent toxicity.
  • Findings emphasize the need for individualized dosing and vigilant observation in pediatric patients.

More Related Videos

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease04:21

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease

Published on: August 4, 2021

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery09:47

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery

Published on: June 2, 2022

Related Concept Videos

Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...